TESARO (TSRO) Misses Q1 EPS by 18c, Completes Enrollment in Phase 3 NOVA Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TESARO Announces Completion of Targeted Enrollment in Phase 3 NOVA Trial and Initiation of the QUADRA Trial of Niraparib
April 30, 2015 4:02 PM EDTBoth the non-germline and germline BRCA mutation cohorts within NOVA are fully enrolled Phase 3 data from NOVA is expected in Q4 2015 Patients are now being treated within the QUADRA trial
WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today provided an update on its niraparib clinical development program. The targeted enrollment has been achieved in both patient cohorts of the Phase 3 NOVA trial of niraparib, and TESARO expects data from NOVA in the fourth quarter of 2015. In addition, the QUADRA... More
TESARO Announces First-Quarter 2015 Operating Results
April 30, 2015 4:01 PM EDTTarget enrollment completed for both cohorts of the niraparib Phase 3 NOVA trial; data expected in Q4 2015 QUADRA trial of niraparib initiated; initial data anticipated in early 2016 U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015 Cash and cash equivalents totaled approximately $399 million as of March 31, 2015
WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today reported operating results for first-quarter 2015 and provided an update on the Company's development programs.
"During the first quarter,... More
